Point72 DIFC Ltd Acquires Shares of 26,062 Natera, Inc. (NASDAQ:NTRA)

Point72 DIFC Ltd bought a new position in Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 26,062 shares of the medical research company’s stock, valued at approximately $3,309,000.

A number of other hedge funds have also made changes to their positions in NTRA. Covestor Ltd increased its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares in the last quarter. CIBC Asset Management Inc lifted its position in Natera by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after buying an additional 111 shares in the last quarter. RiverPark Advisors LLC grew its holdings in Natera by 3.5% during the 3rd quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock worth $425,000 after acquiring an additional 112 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC increased its position in Natera by 5.4% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after acquiring an additional 135 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, Director Rowan E. Chapman sold 2,614 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $127.68, for a total transaction of $333,755.52. Following the completion of the transaction, the director now directly owns 7,969 shares of the company’s stock, valued at approximately $1,017,481.92. This represents a 24.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gail Boxer Marcus sold 9,682 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $159.98, for a total value of $1,548,926.36. Following the transaction, the director now directly owns 9,704 shares in the company, valued at $1,552,445.92. This trade represents a 49.94 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 46,503 shares of company stock valued at $6,325,804. 7.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research analyst reports. TD Cowen increased their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Canaccord Genuity Group increased their price objective on Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Morgan Stanley upped their price target on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Stephens reiterated an “overweight” rating and issued a $125.00 price objective on shares of Natera in a research report on Friday, August 9th. Finally, Piper Sandler upped their target price on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $140.59.

Natera Stock Down 0.4 %

Natera stock opened at $169.17 on Wednesday. Natera, Inc. has a twelve month low of $55.56 and a twelve month high of $171.95. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company has a 50 day moving average of $137.36 and a 200-day moving average of $121.28. The stock has a market capitalization of $22.33 billion, a PE ratio of -96.12 and a beta of 1.63.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.95) EPS. On average, equities research analysts anticipate that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.